Altimmune (ALT) Free Cash Flow (2010 - 2026)

Altimmune (ALT) has 17 years of Free Cash Flow data on file, last reported at -$21.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 24.48% year-over-year to -$21.0 million in Q1 2026; TTM through Mar 2026 was -$71.7 million, a 10.8% increase from a year earlier, with the FY2025 full-year figure at -$67.5 million, up 15.41% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$21.0 million, down from -$19.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for ALT reached as high as -$11.9 million in Q3 2025 and fell as low as -$27.1 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$18.1 million across 5 years, with a median of -$18.1 million in 2024.
• Across the five-year window, Free Cash Flow tumbled 43.76% in 2023 and jumped 56.13% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$17.3 million in 2022, then advanced by 4.68% to -$16.5 million in 2023, then dropped by 10.48% to -$18.3 million in 2024, then dropped by 6.48% to -$19.4 million in 2025, then retreated by 7.78% to -$21.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$21.0 million in Q1 2026, -$19.4 million in Q4 2025, and -$11.9 million in Q3 2025.